-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Increase R&D and let R&D stand on the "C" position to gain a firm foothold in the industry
.
In the pharmaceutical industry, R&D investment is even more important for pharmaceutical companies to maintain their competitiveness
.
It is understood that in recent years, China's pharmaceutical companies have begun to continuously shift to "research and development", and many listed pharmaceutical companies have shown strong willingness to invest in research and development
.
Data shows that in the first three quarters of this year, some listed pharmaceutical companies invested more than 100 million yuan in research and development, and their share of revenue continued to increase
.
For example, Hengrui Pharmaceutical's R&D expenses increased by nearly 24% year-on-year, reaching 4.
142 billion yuan, accounting for more than 20% of revenue; Fosun Pharma’s R&D expenses increased by more than 28% year-on-year to 2.
414 billion yuan; Mindray Medical R&D investment increased by 19% year-on-year , Nearly 1.
8 billion yuan; Yiling Pharmaceutical's R&D expenses increased by nearly 38% year-on-year to 538 million yuan; Fudan Zhangjiang's R&D expenses increased by about 66% year-on-year to approximately 178 million yuan, accounting for 25.
54% of total revenue; Shanghai Pharmaceutical research and development expenses increased by 31.
38% year-on-year to 1.
367 billion yuan
.
Among them, Fosun Pharma stated that since the beginning of this year, Fosun Pharma has continuously strengthened its innovative research and development capabilities, enriched and consolidated its product line, continued to promote the development of innovative products and technologies, and strengthened its commercialization system
.
In terms of product research and development, the joint venture Fosun Kate’s Yikaida (Akielunsai injection) has been actively exploring innovative payment models since it was approved for listing in June 2021; the development and commercialization of macromolecular drugs has been steadily advancing.
Lizumab injection (ie recombinant anti-PD-1 humanized monoclonal antibody injection) Shanghai Xuhui base production line passed the GMP on-site inspection in September 2021, and the drug registration application for its second indication was applied in September 2021 Accepted by the National Food and Drug Administration; Trastuzumab for injection (trade name: Hanquyou) was approved to add a new 60mg specification, further enriching clinical drug choices
.
Shanghai Pharmaceuticals said that after years of investment in innovation, the company is gradually entering the harvest period
.
For example, the announcement of “About Shanghai Pharmaceuticals Licenses SPH6162 Overseas Rights and Interests to HUYABIO” shows that Shanghai Pharmaceuticals’ first overseas lisence-out formally landed, and Shanghai Pharmaceuticals has cooperated with the US HUYABIO International on the overseas authorization of the new anti-tumor drug SPH6162 independently developed.
) Reach cooperation
.
Fudan Zhangjiang said that in the future, in the domestic market, Fudan Zhangjiang will focus on consolidating its core R&D technical advantages, enriching product catalogs, and promoting the industrialization of R&D results.
Based on existing products, it will strengthen R&D and innovation to provide patients with more Value and differentiated products and services
.
Pharmaceutical R&D expenditures are the foundation that drives the development of the industry
.
In recent years, China's pharmaceutical companies have continuously increased their R&D investment.
According to data, the scale of pharmaceutical R&D investment in 2020 will reach US$25.
3 billion
.
In addition, according to a set of data in the reply letter to the committee's proposal recently issued by the National Medical Insurance Administration, the sales expenses of listed A-share pharmaceutical companies in 2020 have shown a downward trend for the first time in the past five years, a year-on-year decrease of 6%, and R&D expenses increased by 22% year-on-year
.
In the context of increasing investment in research and development, China's innovative drug industry is also gradually rising
.
In 2020, the number of domestic new drugs approved for the whole year reached 11, reaching double digits for the first time.
They were clopavir, ametinib, zebutinib, remazolam, lavidavir, and en Satinib, cyclopofol, fluzoparib, imitavir, obetinib, and sofatinib; among them, 6 are new tumor drugs, 2 are new anesthesia drugs, and 3 are new hepatitis C drugs
.
The number of domestic new drugs approved reached 11, reaching double digits for the first time
.
Among them, 6 are new tumor drugs, 2 are new anesthesia drugs, and 3 are new hepatitis C drugs
.
It is expected that in the future, the number of domestic new drugs approved each year is expected to further increase, reaching the level of 10-20
.
.
In the pharmaceutical industry, R&D investment is even more important for pharmaceutical companies to maintain their competitiveness
.
It is understood that in recent years, China's pharmaceutical companies have begun to continuously shift to "research and development", and many listed pharmaceutical companies have shown strong willingness to invest in research and development
.
Data shows that in the first three quarters of this year, some listed pharmaceutical companies invested more than 100 million yuan in research and development, and their share of revenue continued to increase
.
For example, Hengrui Pharmaceutical's R&D expenses increased by nearly 24% year-on-year, reaching 4.
142 billion yuan, accounting for more than 20% of revenue; Fosun Pharma’s R&D expenses increased by more than 28% year-on-year to 2.
414 billion yuan; Mindray Medical R&D investment increased by 19% year-on-year , Nearly 1.
8 billion yuan; Yiling Pharmaceutical's R&D expenses increased by nearly 38% year-on-year to 538 million yuan; Fudan Zhangjiang's R&D expenses increased by about 66% year-on-year to approximately 178 million yuan, accounting for 25.
54% of total revenue; Shanghai Pharmaceutical research and development expenses increased by 31.
38% year-on-year to 1.
367 billion yuan
.
Among them, Fosun Pharma stated that since the beginning of this year, Fosun Pharma has continuously strengthened its innovative research and development capabilities, enriched and consolidated its product line, continued to promote the development of innovative products and technologies, and strengthened its commercialization system
.
In terms of product research and development, the joint venture Fosun Kate’s Yikaida (Akielunsai injection) has been actively exploring innovative payment models since it was approved for listing in June 2021; the development and commercialization of macromolecular drugs has been steadily advancing.
Lizumab injection (ie recombinant anti-PD-1 humanized monoclonal antibody injection) Shanghai Xuhui base production line passed the GMP on-site inspection in September 2021, and the drug registration application for its second indication was applied in September 2021 Accepted by the National Food and Drug Administration; Trastuzumab for injection (trade name: Hanquyou) was approved to add a new 60mg specification, further enriching clinical drug choices
.
Shanghai Pharmaceuticals said that after years of investment in innovation, the company is gradually entering the harvest period
.
For example, the announcement of “About Shanghai Pharmaceuticals Licenses SPH6162 Overseas Rights and Interests to HUYABIO” shows that Shanghai Pharmaceuticals’ first overseas lisence-out formally landed, and Shanghai Pharmaceuticals has cooperated with the US HUYABIO International on the overseas authorization of the new anti-tumor drug SPH6162 independently developed.
) Reach cooperation
.
Fudan Zhangjiang said that in the future, in the domestic market, Fudan Zhangjiang will focus on consolidating its core R&D technical advantages, enriching product catalogs, and promoting the industrialization of R&D results.
Based on existing products, it will strengthen R&D and innovation to provide patients with more Value and differentiated products and services
.
Pharmaceutical R&D expenditures are the foundation that drives the development of the industry
.
In recent years, China's pharmaceutical companies have continuously increased their R&D investment.
According to data, the scale of pharmaceutical R&D investment in 2020 will reach US$25.
3 billion
.
In addition, according to a set of data in the reply letter to the committee's proposal recently issued by the National Medical Insurance Administration, the sales expenses of listed A-share pharmaceutical companies in 2020 have shown a downward trend for the first time in the past five years, a year-on-year decrease of 6%, and R&D expenses increased by 22% year-on-year
.
In the context of increasing investment in research and development, China's innovative drug industry is also gradually rising
.
In 2020, the number of domestic new drugs approved for the whole year reached 11, reaching double digits for the first time.
They were clopavir, ametinib, zebutinib, remazolam, lavidavir, and en Satinib, cyclopofol, fluzoparib, imitavir, obetinib, and sofatinib; among them, 6 are new tumor drugs, 2 are new anesthesia drugs, and 3 are new hepatitis C drugs
.
The number of domestic new drugs approved reached 11, reaching double digits for the first time
.
Among them, 6 are new tumor drugs, 2 are new anesthesia drugs, and 3 are new hepatitis C drugs
.
It is expected that in the future, the number of domestic new drugs approved each year is expected to further increase, reaching the level of 10-20
.
